MCID: 49X004
MIFTS: 28

49,xyyyy Syndrome

Categories: Fetal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for 49,xyyyy Syndrome

Summaries for 49,xyyyy Syndrome

Orphanet: 58 A rare Y chromosome number anomaly with a variable phenotype mainly characterized by moderate to severe intellectual disability, speech delay, hypotonia, and mild dysmorphic features, including facial asymmetry, hypertelorism, bilateral low set 'lop' ears, and micrognatia. Skeletal abnormalities (such as skull deformities, radioulnar synostosis, elbow flexion, clinodactyly, brachydactyly) and behavourial problems have also been associated with this condition. Genitalia are normal at birth, although hypogonadism and azoospermia has been reported in adults.

MalaCards based summary: 49,xyyyy Syndrome, also known as xyyyy syndrome, is related to 47 xxx syndrome and 49, xxxxy syndrome. The drugs Heptavalent Pneumococcal Conjugate Vaccine and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include testis, breast and colon, and related phenotypes are intellectual disability and scoliosis

Wikipedia: 75 XYYYY syndrome, also known as 49,XYYYY, is an exceptionally rare chromosomal disorder in which a male... more...

Related Diseases for 49,xyyyy Syndrome

Diseases related to 49,xyyyy Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 15)
# Related Disease Score Top Affiliating Genes
1 47 xxx syndrome 10.3
2 49, xxxxy syndrome 10.3
3 hypogonadotropic hypogonadism 10.2
4 turner syndrome 10.2
5 synostosis 10.1
6 down syndrome 10.1
7 autism 10.1
8 anxiety 10.1
9 brachydactyly 10.1
10 autism spectrum disorder 10.1
11 inguinal hernia 10.1
12 separation anxiety disorder 10.1
13 mutism 10.1
14 48,xyyy 10.1
15 elective mutism 10.1

Graphical network of the top 20 diseases related to 49,xyyyy Syndrome:



Diseases related to 49,xyyyy Syndrome

Symptoms & Phenotypes for 49,xyyyy Syndrome

Human phenotypes related to 49,xyyyy Syndrome:

58 30 (show all 44)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 intellectual disability 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001249
2 scoliosis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002650
3 hypotonia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001252
4 coarse facial features 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000280
5 delayed skeletal maturation 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002750
6 hypertelorism 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000316
7 delayed speech and language development 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000750
8 recurrent upper respiratory tract infections 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002788
9 increased circulating gonadotropin level 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000837
10 cubitus valgus 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002967
11 micrognathia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000347
12 low-set, posteriorly rotated ears 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000368
13 azoospermia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000027
14 ventriculomegaly 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002119
15 radioulnar synostosis 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002974
16 gynecomastia 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000771
17 decreased testicular size 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0008734
18 moderate global developmental delay 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0011343
19 abnormal cerebral white matter morphology 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002500
20 low frustration tolerance 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000744
21 male hypogonadism 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0000026
22 impulsivity 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100710
23 short 5th finger 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0009237
24 primary gonadal insufficiency 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0008193
25 finger clinodactyly 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0040019
26 eunuchoid habitus 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003782
27 abnormality of the epiphyses of the elbow 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0003946
28 large carpal bones 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0004237
29 bridged palmar crease 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0011310
30 decreased serum testosterone concentration 30 Hallmark (90%) HP:0040171
31 turricephaly 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000262
32 lower limb asymmetry 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0100559
33 large hands 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0001176
34 trigonocephaly 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000243
35 developmental cataract 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000519
36 generalized joint laxity 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002761
37 lop ear 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0000394
38 global developmental delay 58 Very frequent (99-80%)
39 behavioral abnormality 58 Very frequent (99-80%)
40 abnormal facial shape 58 Very frequent (99-80%)
41 abnormality of the genitourinary system 58 Very frequent (99-80%)
42 external genital hypoplasia 58 Very frequent (99-80%)
43 decreased serum testosterone level 58 Very frequent (99-80%)
44 abnormality of the testis size 58 Very frequent (99-80%)

Drugs & Therapeutics for 49,xyyyy Syndrome

Drugs for 49,xyyyy Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 62)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
2 Immunologic Factors Phase 4
3
Cocaine Approved, Illicit Phase 3 50-36-2 446220 5760
4
Aluminium phosphate Approved, Investigational Phase 3 7784-30-7
5
Fluticasone Approved, Experimental Phase 2, Phase 3 90566-53-3 4659387 5311101
6 Hemagglutinins Phase 3
7 Agglutinins Phase 3
8 Bronchodilator Agents Phase 2, Phase 3
9 Anti-Asthmatic Agents Phase 2, Phase 3
10 Anti-Allergic Agents Phase 2, Phase 3
11 Xhance Phase 2, Phase 3
12 Respiratory System Agents Phase 2, Phase 3
13 Anti-Inflammatory Agents Phase 2, Phase 3
14 Dermatologic Agents Phase 2, Phase 3
15 polysaccharide-K Phase 3
16
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
17
Aflibercept Approved Phase 2 862111-32-8 124490314
18
Fluorouracil Approved Phase 2 51-21-8 3385
19
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
20
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
21
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
22
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
23
Pemetrexed Approved, Investigational Phase 2 150399-23-8, 137281-23-3 60843 446556 135565230
24
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
25
Sargramostim Approved, Investigational Phase 2 123774-72-1
26
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
27
Molgramostim Investigational Phase 2 99283-10-0
28 N-(2-aminoethyl)-5-isoquinolinesulfonamide Phase 1, Phase 2
29 Angiogenesis Inhibitors Phase 2
30 Folate Phase 2
31 Vitamin B9 Phase 2
32 Vitamin B Complex Phase 2
33 Folic Acid Antagonists Phase 2
34 Albumin-Bound Paclitaxel Phase 2
35 Antimitotic Agents Phase 2
36 Tubulin Modulators Phase 2
37 Antineoplastic Agents, Immunological Phase 2
38
Metformin Approved Phase 1 1115-70-4, 657-24-9 4091
39
Aluminum sulfate Approved Phase 1 10043-01-3
40 Immunoglobulins Phase 1
41 Antibodies Phase 1
42
Ethanol Approved 64-17-5 702
43
Bortezomib Approved, Investigational 179324-69-7 387447 93860
44
Iron Approved 7439-89-6 29936
45
Iodine Approved, Investigational 7553-56-2 807
46
Mecobalamin Approved, Investigational 13422-55-4
47
Hydroxocobalamin Approved 13422-51-0 15589840 44475014
48
Testosterone Approved, Investigational 58-22-0 5408 6013
49
Cyanocobalamin Approved, Nutraceutical 68-19-9 24892734 16212801 44176380
50
Cadexomer iodine Experimental 94820-09-4

Interventional clinical trials:

(show top 50) (show all 87)
# Name Status NCT ID Phase Drugs
1 A Randomized, Open-Label, Study to Evaluate the Immunogenicity of One Dose of Live Attenuated Influenza Vaccine (LAIV) Compared to One Dose of Trivalent Inactivated Influenza Vaccine (IIV) in Adults 18-49 Years of Age Completed NCT03101462 Phase 4
2 An Open-Label, Single-Arm Trial to Assess the Shedding, Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age Completed NCT00192140 Phase 4
3 A PHASE 4, OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO DESCRIBE THE SAFETY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS 18 TO 49 YEARS OF AGE IN INDIA Active, not recruiting NCT05329259 Phase 4
4 A Randomized, Double-Blind, Placebo Controlled Trial to Evaluate the Efficacy of Fluviral™ Influenza Vaccine in Healthy Adults 18 to 49 Years of Age Unknown status NCT00216242 Phase 3
5 Double-Blind, Randomized, Active-Controlled Comparison of the Immunogenicity and Safety of Flublok® Quadrivalent Versus IIV4 in Healthy, Medically Stable Adults 18-49 Years of Age Completed NCT02290509 Phase 3
6 A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF 3 LOTS OF 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN PNEUMOCOCCAL VACCINE-NAÏVE ADULTS 18 THROUGH 49 YEARS OF AGE Completed NCT03828617 Phase 3
7 A Phase III, Randomized, Multi-country Study to Evaluate the Lot-to-lot Consistency of GSK's Investigational RSV Maternal Vaccine and the Immune Response, Safety and Reactogenicity of RSV Maternal Vaccine When Co-administered With GSK's Quadrivalent Influenza D-QIV Vaccine in Healthy Non-pregnant Women 18-49 Years of Age. Completed NCT05045144 Phase 3
8 A Randomized, Double-Blind, Active Controlled Study to Evaluate the Immunogenicity of MEDI3250 in Adults 18 to 49 Years of Age Completed NCT00860067 Phase 2, Phase 3
9 A Randomized, Observer-blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency, Immunogenicity, and Safety of a Plant-Derived Quadrivalent Virus-Like Particle Influenza Vaccine in Healthy Adults 18-49 Years of Age Completed NCT03321968 Phase 3
10 Evaluation of the Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok® Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine in Healthy Adults Aged 18 to 49 Years Completed NCT00539981 Phase 3
11 A Randomized, Partially Blind Active Controlled Study to Evaluate the Immunogenicity of MEDI8662 in Adults 18 to 49 Years of Age Completed NCT00952705 Phase 3
12 A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by Administration of PNEUMOVAX™23 Six Months Later in Immunocompetent Adults Between 18 and 49 Years of Age at Increased Risk for Pneumococcal Disease (PNEU - DAY) Completed NCT03547167 Phase 3
13 A Prospective, Double-Blind, Randomized Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants Ages 5 Through 49 Years Completed NCT00192335 Phase 3
14 A Phase III, Randomized, Controlled, Observer-Blind, Single-Center Study to Evaluate the Consistency of Three Consecutive Lots of a Trivalent Subunit Influenza Vaccine Produced in Embryonated Hen Eggs in Healthy Subjects Aged 18 to 49 Years Completed NCT00617851 Phase 3
15 Evaluation of the Immunogenicity and Safety of Two Preparations of Trivalent Recombinant Baculovirus-Expressed Hemagglutinin Influenza Vaccine Administered Intramuscularly in Healthy Adults Ages 18-49 Years. Completed NCT00328107 Phase 2, Phase 3
16 A Phase II/III Double Blinded, Randomized, Controlled, Non-inferiority Trial to Evaluate the Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Subjects Aged 18-49 Years Completed NCT03390166 Phase 2, Phase 3
17 A Phase III, Open-Label Clinical Trial to Study the Safety and Immunogenicity of V110 in Subjects 50 Years of Age and Older and in Subjects 2 to 49 Years of Age at Increased Risk for Pneumococcal Disease, From the Russian Population Completed NCT01734239 Phase 3
18 A Multicenter, Open-label, Randomized Controlled Trial to Evaluate the Efficacy of Fluticasone Propionate MDI Added to Standard Care at Early Stage of COVID-19 in Reducing the Incidence of Adverse Outcomes in Symptomatic Patients Either From 18 to 49 Year Old With Risk Factors or Older Than 50 Year Old Recruiting NCT05054322 Phase 2, Phase 3 Fluticasone Propionate
19 Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) in Children and Adolescents Aged 9 to 17 Years and Adults Aged 18 to 49 Years. Recruiting NCT05513053 Phase 3
20 A Phase III, Randomized, Double-blind, Placebo-controlled Multi-country Study to Demonstrate Efficacy of a Single Dose of Unadjuvanted RSV Maternal Vaccine, Administered IM to Pregnant Women 18 to 49 Years of Age, for Prevention of RSV Associated LRTIs in Their Infants up to 6 Months of Age Active, not recruiting NCT04605159 Phase 3 Placebo
21 A Phase III, Randomized, Open-label, Active Vaccine-controlled Crossover Study to Evaluate the Reactogenicity, Safety and Immune Response of Unadjuvanted RSV Maternal Vaccine in Healthy Non-pregnant Girls From 9 to 17 Years of Age, and in Non-pregnant Adult Women From 18 to 49 Years of Age Active, not recruiting NCT05169905 Phase 3
22 A Phase 3 Randomized, Double-blind, Active Comparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Adults 18 to 49 Years of Age Active, not recruiting NCT05464420 Phase 3
23 A Phase III, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety, Reactogenicity and Immune Response of a Single Intramuscular Dose of Unadjuvanted RSV Maternal Vaccine, in High Risk Pregnant Women Aged 15 to 49 Years and Infants Born to the Vaccinated Mothers Active, not recruiting NCT04980391 Phase 3 Placebo
24 A Randomized, Observer-Blind, Multicenter, Phase 3 Study to Evaluate the Lot Consistency of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults 18-49 Years of Age Not yet recruiting NCT05040789 Phase 3
25 A Phase IIIB, Open Label, Non-randomized, Controlled, Multi-country Study to Evaluate Safety, Reactogenicity and Immunogenicity of the Repeat Vaccination With 120 µg Dose of RSV Maternal Vaccine During Subsequent Pregnancy in Healthy Maternal Participants 18-49 Years of Age Withdrawn NCT05229068 Phase 3
26 A PHASE 2b, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE Completed NCT04071158 Phase 2
27 Phase 2b, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Immunogenicity of the Intramuscular Norovirus GI.1/GII.4 Bivalent Virus-like Particle Vaccine in Healthy Adults Aged 18 - 49 Years Completed NCT02669121 Phase 2
28 Immunogenicity of Two Dosages of a Split, Cell-Based, Inactivated, Trivalent Influenza Vaccine Administered in Healthy Adult Subjects Aged 18 to 49 Years Completed NCT00845429 Phase 2
29 A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and SAfety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-49) Adults Completed NCT02307851 Phase 2
30 A Phase I/II, First-in-human, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of TAP-COVID-19 SARS-CoV-2 Vaccine With CpG Adjuvant in Healthy Adults Aged 18-49 and 50-85 Completed NCT04473690 Phase 1, Phase 2
31 A PHASE 2B, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS Completed NCT04032093 Phase 2
32 A Two-Part Placebo-Controlled Evaluation of the Safety and Immunogenicity of an A/Indonesia/5/05 Recombinant Hemagglutinin Influenza H5N1 Vaccine With and Without Glucopyranosyl Lipid A (GLA-SE) in Healthy Adults 18-49 Completed NCT01147068 Phase 1, Phase 2
33 A PHASE 1/2, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY ADULTS 18 TO 49 YEARS OF AGE Completed NCT03170609 Phase 2
34 Phase 2 Observer-Blind, Randomized Trial to Evaluate the Immunogenicity and Safety of PanBlok at Three Dose Levels Adjuvanted With a Stable Oil-in-Water Emulsion Compared With PanBlok Without Adjuvant in Healthy Adults Aged 18 to 49 Years Completed NCT01612000 Phase 1, Phase 2
35 Preference for Fluzone Vaccine Administered Intradermally Versus Intramuscularly in Healthy Adult Subjects 18-49 Years of Age Completed NCT00623181 Phase 2
36 A Phase I/II Randomized Double Blind Controlled Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Split Virion Influenza Vaccine in Healthy Thai Adults Aged Between 18 Years to 49 Years Completed NCT02894840 Phase 1, Phase 2
37 A Randomized, Observer-Blind, Controlled Phase 1/2a Study of the Safety, Tolerability and Immunogenicity of Fluzone Administered With and Without LIQ001 in Two Cohorts of Healthy Subjects: 18-49 Years of Age and 65 Years of Age or Older. Completed NCT01224262 Phase 1, Phase 2
38 A Randomized, Double Blind, Multi-center, Phase 1/2 Study to Assess Safety and Immunogenicity of Five Dose Levels of a Reverse Genetic (RG) Reassortant H9N2 Pandemic Influenza Vaccine in Healthy Subjects Aged 18 to 49 Years Completed NCT01320696 Phase 1, Phase 2
39 OPTIMOX-aflibercept as First-line Therapy in 49 Patients With Unresectable Metastatic Colorectal Cancer. A GERCOR Feasibility Single-arm Phase II Study. Completed NCT01802684 Phase 2
40 A Phase II Trial of GM-CSF Plus Maintenance Pembrolizumab +/- Pemetrexed After Completion of First Line Chemo-Immunotherapy in Advanced Non-Small Cell Lung Cancer Patients With PDL-1 of 1%-49% Recruiting NCT04856176 Phase 2 Granulocyte-Macrophage Colony-Stimulating Factor;Pembrolizumab;pemetrexed;Paclitaxel;Carboplatin
41 A PHASE 2B, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLINDED TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE Active, not recruiting NCT04766086 Phase 2
42 A Phase 2a/b, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of OG-6219 in 3 Dose Levels, in Women 18 to 49 Years of Age With Moderate to Severe Endometriosis-related Pain Not yet recruiting NCT05560646 Phase 2 OG-6219;Placebo
43 Phase I Randomized Double Blind Placebo-controlled Study of Universal Influenza Vector Vaccine "UniFluVec" of Two Dose Levels After Two Intranasal Administrations in Healthy Volunteers at the Age From 18 to 49 Years Old Completed NCT04650971 Phase 1
44 A Randomized, Double-blind, Placebo-controlled Study of the Effect of 49 Days of Treatment With Repeated Subcutaneous Doses of HIP2B to Assess Safety, Tolerability and Measures of Islet β-cell Function in Subjects With Type 2 Diabetes Mellitus Treated With Metformin Completed NCT01933256 Phase 1 HIP2B;Placebo
45 A Phase I Study of the Safety and Immunogenicity of the Recombinant Live-Attenuated Human Parainfluenza Type 1 Virus Vaccine, rHPIV1 84/del170/942A, Lot PIV1 #104A, Delivered as Nose Drops to Adults 18 to 49 Years of Age, HPIV1-Seropositive Children 15 to 59 Months of Age, and HPIV1-Seronegative Infants and Children 6 to 59 Months of Age Completed NCT00641017 Phase 1
46 A Two Part Study to Investigate the Safety and Immunogenicity of the VAX125 Influenza Vaccine in Healthy Adults Age 18-49 Years Part I: Phase I, Open-Label, Escalating Dose-Ranging Study Part II: Phase II, Double-Blind Placebo-Controlled Study Completed NCT00730457 Phase 1
47 A Phase 1, Randomized, Observer-Blind, Placebo-Controlled, Safety, Immunogenicity, and Dose Ranging Study of Purified Inactivated Zika Virus Vaccine (PIZV) Candidate in Flavivirus Naïve and Primed Healthy Adults Aged 18 to 49 Years Completed NCT03343626 Phase 1 Placebo
48 A Phase 1, Randomized, Controlled, Observer-blinded Trial To Evaluate The Safety And Immunogenicity Of A Multivalent Pneumococcal Conjugate Vaccine In Healthy Adults Aged 18 To 49 Years Completed NCT02955160 Phase 1
49 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years. Completed NCT00599443 Phase 1
50 A First-in-human Phase I, Single Center, Randomized, Observer-blind, Placebo-controlled Study to Evaluate the Safety and Immune Response of Increasing Doses of OVX836 Vaccine After Intramuscular (IM) or Intranasal (IN) Administrations in Healthy Subjects Aged 18-49 Years. Completed NCT03594890 Phase 1

Search NIH Clinical Center for 49,xyyyy Syndrome

Genetic Tests for 49,xyyyy Syndrome

Anatomical Context for 49,xyyyy Syndrome

Organs/tissues related to 49,xyyyy Syndrome:

MalaCards : Testis, Breast, Colon, Lung

Publications for 49,xyyyy Syndrome

Articles related to 49,xyyyy Syndrome:

# Title Authors PMID Year
1
Autism spectrum disorder associated with 49,XYYYY: case report and review of the literature. 62
28137251 2017
2
[A 7-year-old boy with 49,XYYYY syndrome]. 62
3261145 1988
3
[The 49,XYYYY syndrome: apropos of a case detected at birth and followed for 2 1/2 years]. 62
6491641 1984

Variations for 49,xyyyy Syndrome

Expression for 49,xyyyy Syndrome

Search GEO for disease gene expression data for 49,xyyyy Syndrome.

Pathways for 49,xyyyy Syndrome

GO Terms for 49,xyyyy Syndrome

Sources for 49,xyyyy Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....